Healthcare IPO outlook in Singapore dims; Takeda gets MHLW Leuplin nod;

> Hopes for initial public share sales in Singapore in healthcare have been dashed in 2015 after promise in July when drugmaker iX Biopharma listed. But little else in that space is coming down the pipeline, the Straits Times says. Report

> Japan's Takeda Pharmaceutical was granted Ministry of Health, Labour and Welfare New Drug Application approval for Leuplin to treat prostate cancer and premenopausal breast cancer. Release

> HK-listed Shineway Pharmaceuticals paid RMB400 million ($62.8 million) to buy Beijing Wanter Bio's P. aeruginosa vaccine, which is aimed at fighting the spread of gram-negative bacteria that can infect humans and animals and be transmitted in multiple environments. Release (PDF)

> U.S.-based iNeedMD Holdings said the China FDA registered its telemedicine-enabling EKG Glove used in conjunction with electrocardiograms to speed up electrode placement as well. The company is scouting for partners and hopes to have China distribution and sales in place by the end of the year. Release (PDF)